FORTÉBIO Biologics by Molecular Devices
FortéBio’s best-in-class technology platforms encompass workflows from antibody discovery and cell line development through to biomolecular analysis of the biologic product. FortéBio’s products span multiple platforms that include real-time, label-free biomolecular interaction characterisation, clone picking and imaging systems. Biomolecular detection systems include the BLItz and Octet platforms based on fluidics-free biolayer interferometry (BLI) and Pioneer platforms based on next generation surface plasmon resonance (SPR) technology. Clone screening platforms include the QPix 400 series of microbial colony pickers, the ClonePix 2 mammalian colony picker system and the CloneSelect Imager cell imaging system.
FortéBio’s product range offers complete integrated solutions to fast-track early stage biologics development.
FortéBio is a world leader in label-free analysis of biomolecular detection and characterisation, enabling the acceleration of drug discovery and development. Founded in Menlo Park, California in 2001, FortéBio developed next-generation real-time, label-free protein interaction systems based on their proprietary BLI technology. FortéBio’s automated Octet systems provide simple, rapid, reliable and high throughput screening and characterisation of biomolecule interactions that is unparalleled with comparative label free technologies.
Previously a division of Pall Life Sciences, FortéBio is now a part of Molecular Devices; and part of the Danaher Corporation. Danaher is a science and technology innovator committed to improving quality of life around the world. After a restructure within Danaher to better align the product portfolio, FortéBio now forms the Biologics Solutions unit for Molecular Devices, offering complete integrated solutions and support for enabling the acceleration of biologics from discovery to approval.